SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
Rhea-AI Summary
SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, has appointed Dr. Linghua Wang to its Scientific Advisory Board. Dr. Wang, a tenured Associate Professor at MD Anderson's Department of Genomic Medicine, brings extensive expertise in cancer immunogenomics and computational biology.
Dr. Wang leads the Computational Biology Laboratory at MD Anderson and holds multiple prestigious positions, including Associate Member of The James P. Allison Institute. Her research focuses on understanding tumor ecosystems using advanced technologies like single-cell and spatial omics, AI-driven pathology, and machine learning. With over 100 publications and multiple NIH/NCI grants, her expertise aligns with SELLAS's focus on translational research and precision medicine.
Positive
- Addition of highly qualified expert Dr. Wang strengthens the Scientific Advisory Board
- Dr. Wang's expertise in AI and computational biology aligns with company's research focus
- Company approaching key clinical milestones for both assets later this year
Negative
- None.
News Market Reaction – SLS
On the day this news was published, SLS declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company’s SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD.
“We are thrilled to welcome Dr. Wang to our Scientific Advisory Board,” said Dragan Cicic, MD, Senior Vice President, Chief Development Officer of SELLAS. “Her decades of experience in cancer immunogenomics and computational biology are directly aligned with our focus on translational research, artificial intelligence utilization around genomics, proteomics as well as transcriptomics, and precision medicine. With the recent additions of Drs. Amrein and Kentsis, we are building a uniquely experienced and visionary team that will help guide our scientific and clinical strategy during this critical phase of growth. Their collective insights will be invaluable as we approach key clinical milestones expected for both of our assets later this year.”
Dr. Wang is a tenured Associate Professor in the Department of Genomic Medicine at MD Anderson, where she leads the Computational Biology Laboratory. She also holds a dual appointment as an Associate Member of The James P. Allison Institute, serves as Co-Lead of Focus Area 2 (Single-Cell Analytics & Spatial Multi-Omics) at the Institute for Data Science in Oncology, and is a faculty member in the Quantitative Sciences and Immunology PhD Programs at the UTHealth Houston Graduate School of Biomedical Sciences. Trained in Clinical Medicine, she earned her PhD in Cancer Genomics from the University of Tokyo and completed postdoctoral training at Baylor College of Medicine, where she was subsequently promoted to faculty. She was recruited to MD Anderson Cancer Center in 2017.
Her research focuses on unraveling complex tumor ecosystems, with an emphasis on understanding cellular and molecular heterogeneity and dynamics, phenotypic plasticity, and interactions between cancer cells and the tumor microenvironment that drive disease progression and therapy response. Her group leverages cutting-edge single-cell and spatial omics, molecular imaging, AI-driven pathology, and advanced bioinformatics and machine learning approaches to enable transformative discoveries. Dr. Wang’s work aims to advance predictive and precision oncology by developing robust models of patient response and uncovering novel therapeutic targets, with the ultimate goal of transforming how cancers and their precursors are detected, classified, and treated. She holds multiple NIH/NCI funded grants, has published over 100 articles in high-impact journals, and is an internationally recognized leader in cancer research. Her work is highly collaborative, spanning national and international partnerships to advance cancer understanding and treatment.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Dr. Wang receives compensation as a member of SELLAS’s Scientific Advisory Board, and this financial relationship has been disclosed to MD Anderson’s Conflict of Interest Committee in accordance with institutional policy.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
FAQ
Who is Dr. Linghua Wang and what is her role at SELLAS Life Sciences (NASDAQ: SLS)?
What expertise does Dr. Wang bring to SELLAS Life Sciences (SLS)?
What are the upcoming milestones for SELLAS Life Sciences in 2025?
How many recent appointments has SELLAS made to its Scientific Advisory Board?
